TL;DR: Tilray Brands (NASDAQ: TLRY) reported record fiscal 2026 results on July 29, posting $915.5 million in revenue — up 11% year-over-year — alongside record adjusted EBITDA of $61.1 million and a dramatically improved net loss of $105.2 million ($1.09/share) versus a $2.2 billion loss in fiscal 2025. The stock surged 8.10% to $4.54 on Friday, July 31, as the market began repricing the company’s diversified global platform. Management guided for adjusted EBITDA of $68–$75 million in fiscal 2027, with an annualized run-rate revenue approaching $1.2 billion.
Market Analysis
Tilray’s fiscal year ended May 31, 2026, and the headline metrics represent a genuine inflection for the Nasdaq-listed cannabis and consumer products company. Revenue of $915.5 million advanced 11% from $821.3 million in fiscal 2025, with all four business segments contributing growth: cannabis (+8% to $268.3 million), beverage (+6% to $254 million), pharmaceutical distribution (+21% to $327.2 million), and wellness (+9% to $65.9 million). The diversification that CEO Irwin Simon has spent seven years assembling is now yielding measurable operating leverage.
The adjusted EBITDA result of $61.1 million — or $63.4 million excluding unanticipated fuel surcharges — marked an 11% improvement over the prior year and came in within management’s guidance range. More notable to long-term investors: adjusted net income improved 87% to $12.2 million ($0.11/share) versus $6.5 million ($0.07/share) in fiscal 2025, representing two consecutive years of adjusted profitability at a scale most cannabis companies have yet to achieve.
The fourth quarter was particularly strong. Q4 revenue rose 25% to $281.7 million, with beverage surging 61% to $105.6 million following the BrewDog acquisition’s consolidation. International cannabis revenue grew 22% year-over-year, extending three consecutive quarters of greater than 20% growth — a trajectory that positions Tilray’s European medical cannabis platform as a structural revenue compounder. Q4 adjusted EBITDA reached a record $31.9 million, up 15% year-over-year, with Q4 gross margins expanding to 32%.
Balance sheet management was equally compelling. Tilray ended fiscal 2026 with approximately $235 million in cash and marketable securities and net debt of less than $1 million — a 95% year-over-year improvement. The company reduced total debt by approximately $60 million during the fiscal year and executed an ATM raise of $87 million gross, including over $50 million in the five trading days surrounding the U.S. government’s announcement of cannabis rescheduling to Schedule III. The BrewDog acquisition, completed for approximately $54 million out of UK administration, added a globally recognized craft brand, 37 pubs, 16 franchise pubs, and an Australian footprint that is already being leveraged to introduce Tilray’s American craft beer brands into international markets.
Regulatory and Market Context
Tilray’s European medical cannabis platform remains its most underappreciated asset among North American investors. In Germany — the company’s fastest-growing international market — Tilray holds approximately 45% market share in medical cannabis oils through a vertically integrated distribution chain anchored by CC Pharma, which reaches approximately 16,000 pharmacies and major wholesalers. International cannabis revenue grew 34% to $84.9 million in fiscal 2026 despite $21.1 million of pricing compression in the German market, with Poland (+73%), Italy (+53%), the UK (+25%), and Germany (+25%) all contributing double-digit gains.
On the U.S. regulatory front, Phase I cannabis rescheduling to Schedule III was enacted in spring 2026, and Tilray’s management acknowledged meaningful momentum toward Phase II whole-plant rescheduling, which is broadly anticipated in fall 2026. The company’s ATM capital raise specifically around the rescheduling announcement reflects strategic positioning rather than opportunistic dilution — Tilray has explicitly stated it will enter U.S. medical cannabis distribution when the FDA regulatory pathway clarifies, deploying its existing pharmaceutical infrastructure, genetics library, and clinical research base.
The Carlsberg partnership, effective January 1, 2027, adds three internationally recognized beer brands — Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc — to Tilray’s 900-distributor U.S. commercial network, providing a near-term revenue catalyst independent of cannabis policy outcomes. Management’s fiscal 2027 guidance of $68–$75 million in adjusted EBITDA implies a double-digit growth rate and a path toward CEO Simon’s stated medium-term aspiration of 15–18% EBITDA margins.
Conclusion
TLRY’s 8.10% Friday session reflected a market beginning to credit a diversified global platform rather than discounting a single-category cannabis risk. The convergence of record adjusted EBITDA, near-zero net debt, a transformative beverage acquisition, and Phase II rescheduling optionality in H2 2026 creates a multi-catalyst setup entering fiscal 2027. The key risk remains execution: integrating BrewDog’s working capital profile, stabilizing U.S. legacy beer brands, and converting European cannabis scale into margin improvement. Q1 fiscal 2027 results — expected August or September — will be the first real test of whether the operating leverage narrative holds. Monitor TLRY alongside the broader cannabis equity complex via the cannabis stock tracker.